Palvella Therapeutics, Inc. (PVLA)

Palvella Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	14.21	7.35	16.05
Cash & Short-Term Investments	14.21	7.35	16.05
Cash Growth	-11.50%	-54.21%	-
Prepaid Expenses	0.44	0.2	0.47
Total Current Assets	16.32	7.55	16.52
Total Assets	16.32	7.55	16.52
Accounts Payable	3.13	0.94	3.18
Accrued Expenses	4.22	1.26	2.44
Other Current Liabilities	0.28	0.17	0.16
Total Current Liabilities	7.64	2.36	5.78
Long-Term Debt	24.07	8.05	32.42
Other Long-Term Liabilities	1.42	1.01	1.5
Total Liabilities	33.12	11.43	39.7
Additional Paid-In Capital	2.38	1.82	1.22
Retained Earnings	-89.78	-76.3	-94.99
Total Common Equity	-87.4	-74.48	-93.78
Shareholders' Equity	-16.8	-3.88	-23.17
Total Liabilities & Equity	16.32	7.55	16.52
Total Debt	24.07	8.05	32.42
Net Cash (Debt)	-9.86	-0.7	-16.36
Net Cash Per Share	-1.72	-0.12	-2.86
Filing Date Shares Outstanding	5.72	5.72	5.72
Total Common Shares Outstanding	5.72	5.72	5.72
Working Capital	8.69	5.19	10.74
Book Value Per Share	-15.28	-13.02	-16.40
Tangible Book Value	-87.4	-74.48	-93.78
Tangible Book Value Per Share	-15.28	-13.02	-16.40

Source: S&P Capital IQ. Standard template. Financial Sources.